Charmacy Pharmaceutical Co Ltd
HKEX:2289
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
CN |
C
|
Charmacy Pharmaceutical Co Ltd
HKEX:2289
|
1.5B HKD | -9.2 | |
US |
Mckesson Corp
NYSE:MCK
|
72.5B USD | 20.8 | ||
US |
Cencora Inc
NYSE:COR
|
44.1B USD | 16.7 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 21 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
23.6B USD | 7.6 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 7.2 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -236.8 | |
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
66.9B HKD | 4.9 | ||
IT |
Amplifon SpA
MIL:AMP
|
7.5B EUR | 33.8 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
57.5B CNY | 24.2 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
52B CNY | 12.1 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.